Clinical trial
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in…
NCT00001145 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001145 |
|---|---|
| Title | Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome |
| Official title | Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Immunoproliferative Disorder |
| Intervention type | Drug |
| Interventions | Bacteriophage, rhuCD40L, KLH |
| Enrollment | 5 |
| Start date | Oct 1, 1999 |
| Completion | Oct 1, 2003 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: